VERA — Vera Therapeutics Cashflow Statement
0.000.00%
- $2.16bn
- $1.73bn
- 44
- 15
- 39
- 23
Annual cashflow statement for Vera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -53.4 | -32.6 | -89.1 | -96 | -152 |
| Depreciation | |||||
| Non-Cash Items | 18.2 | 5.21 | 14.7 | 9.68 | 14.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.123 | 3.51 | 6.75 | -5.87 | 2.66 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -34.8 | -23.7 | -67.6 | -92.2 | -135 |
| Capital Expenditures | -0.099 | -5 | -0.062 | -0.063 | -0.972 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.057 | 0.796 | -70.5 | -39.4 | -424 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.042 | -4.2 | -70.6 | -39.4 | -425 |
| Financing Cash Flow Items | -0.412 | -2.77 | -6.1 | -7.26 | -39.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 85.3 | 53.9 | 102 | 134 | 607 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 50.4 | 26 | -36.2 | 1.93 | 47 |